Compare · ADXS vs KDMN
ADXS vs KDMN
Side-by-side comparison of Advaxis, Inc. (ADXS) and Kadmon Holdings, Inc. (KDMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and KDMN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KDMN is the larger of the two at $1.67B, about 29.9x ADXS ($56.0M).
- KDMN has more recent analyst coverage (3 ratings vs 0 for ADXS).
- Company
- Advaxis, Inc.
- Kadmon Holdings, Inc.
- Price
- $0.25-15.74%
- $9.49+0.11%
- Market cap
- $56.0M
- $1.67B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 3
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Kadmon Holdings, Inc.
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest KDMN
- Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- SEC Form 15-12B filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company
- SEC Form 4 filed by Cohen David E
- SEC Form 4 filed by Ryan John L
- SEC Form 4: Waksal Harlan returned $1,690,478 worth of shares to the company (177,945 units at $9.50), closing all direct ownership in the company
- SEC Form 4: Moss Gregory S. returned $167,874 worth of shares to the company (17,671 units at $9.50), closing all direct ownership in the company